Recurrent Soft Tissue Sarcoma Suspended Phase 2 Trials for Tazemetostat (DB12887)

IndicationStatusPhase
DBCOND0105100 (Recurrent Soft Tissue Sarcoma)Suspended2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03213665Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)Treatment